Securities Registration: Employee Benefit Plan (s-8)
January 28 2020 - 5:08PM
Edgar (US Regulatory)
As filed with the Securities and Exchange Commission on January 28,
2020
Registration No. 333-____
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
______________________________
FORM S-8
REGISTRATION STATEMENT UNDER
THE SECURITIES ACT OF 1933
______________________________
EDESA BIOTECH, INC.
(Exact
name of registrant as specified in its charter)
British Columbia, Canada
|
|
N/A
|
(State
or other jurisdiction of incorporation or
organization)
|
|
(I.R.S.
Employer Identification No.)
|
100 Spy Court
Markham, Ontario, Canada L3R 5H6
(Address
of Principal Executive Offices) (Zip Code)
Edesa Biotech, Inc. 2019 Equity Incentive Compensation
Plan
(Full
title of the plan)
Kathi Niffenegger
Chief Financial Officer
c/o Edesa Biotech, Inc.
100 Spy Court
Markham, Ontario, Canada L3R 5H6
(Name
and address of agent for service)
(289) 800-9600
(Telephone
number, including area code, of agent for service)
Copies to:
Jonathan Friedman,
Stubbs Alderton & Markiles, LLP
15260 Ventura Blvd.,
20th
Floor, Sherman Oaks, CA,
91403
(818) 444-4500
Indicate
by check mark whether the registrant is a large accelerated filer,
an accelerated filer, a non-accelerated filer, a smaller reporting
company or an emerging growth company. See the definitions of
“large accelerated filer,” “accelerated
filer,” “smaller reporting company,” and
“emerging growth company” in Rule 12b-2 of the Exchange
Act.
Large
accelerated filer
|
☐
|
Accelerated
filer
|
☐
|
Non-accelerated
filer
|
☒
|
Smaller
reporting company
|
☒
|
|
|
Emerging
growth company
|
☒
|
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 7(a)(2)(B) of the Securities
Act. ☒
CALCULATION OF REGISTRATION FEE
Title of
securities to be registered
|
Amount to be
Registered (1)
|
Proposed Maximum
Offering Price Per Share
|
Proposed Maximum
Aggregate Offering Price
|
Amount of
Registration Fee
|
Common Shares, no
par value per share
|
315,123(2)
|
$1.64(3)(4)
|
$516,801.72
|
$67.08
|
Common Shares, no
par value per share
|
119(2)
|
$79.84(3)(4)
|
$9,500.96
|
$1.23
|
Common Shares, no
par value per share
|
214(2)
|
$185.22(3)(4)
|
$39,637.08
|
$5.14
|
Common Shares, no
par value per share
|
214(2)
|
$485.41(3)(4)
|
$103,877.74
|
$13.48
|
Common Shares, no
par value per share
|
238(2)
|
$768.60(3)
|
$182,926.80
|
$23.74
|
Common Shares, no
par value per share
|
238(2)
|
$304.08(3)
|
$72,371.04
|
$9.39
|
Common Shares, no
par value per share
|
24(2)
|
$93.24(3)
|
$2,237.76
|
$0.29
|
Common Shares, no
par value per share
|
738(2)
|
$85.26(3)
|
$62,921.88
|
$8.17
|
Common Shares, no
par value per share
|
2,737(2)
|
$35.28(3)
|
$96,561.36
|
$12.53
|
Common Shares, no
par value per share
|
833,502(5)
|
$3.22(6)
|
$2,683,876.44
|
$348.37
|
Totals
|
1,153,147
|
n/a
|
$3,770,712.78
|
$489.44
|
(1)
Pursuant to Rule
416 under the Securities Act of 1933, as amended (the
“Securities Act”), this registration statement also
covers any additional shares of the registrant’s Common
Shares that become issuable under the Edesa Biotech, Inc. 2019
Equity Incentive Compensation Plan (the “Plan”), by
reason of any share dividend, share split, recapitalization, or any
other similar transaction without receipt of consideration that
results in an increase in the number of the registrant’s
Common Shares.
(2)
Represents Common
Shares subject to share options under the Plan that are outstanding
as of the date this registration statement is being
filed.
(3)
Estimated solely
for purpose of calculating the registration fee in accordance with
Rule 457(h) of the Securities Act. The price per share and
aggregate offering price are based upon the specified exercise
price per share with respect to such securities and have been
calculated in accordance with Rule 457(c) under the Securities
Act.
(4)
The exercise price for these options is denominated in Canadian
currency. The US dollar price reported in this table reflects the
US dollar equivalent exercise price as of January 24, 2020,
calculated at the average of the maximum and minimum bid rates as
reported by OANDA on such date of CDN$1.00 = U.S.
$0.76035.
(5)
Represents Common
Shares available for grant under the Plan as of the date this
registration statement is being filed.
(6)
Estimated solely
for the purpose of calculating the registration fee pursuant to
Rules 457(h) and 457(c) of the Securities Act using the average of
the high and low sales prices of the registrant’s Common
Shares as reported on The Nasdaq Capital Market on January 24,
2020.
INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
Information
required by Item 1 and Item 2 of Part I to be contained in the
Section 10(a) prospectus is omitted from this Registration
Statement in accordance with the provisions of Rule 428 under the
Securities Act and the introductory note to Part I of Form S-8. The
documents containing the information specified in Part I have been
or will be delivered to the participants in the Plan as required by
Rule 428(b). These documents, which include the statement of
availability required by Item 2 of Part I, and the documents
incorporated by reference in this Registration Statement pursuant
to Item 3 of Part II, taken together, constitute a prospectus that
meets the requirements of Section 10(a) of the Securities
Act.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 3. Incorporation of Documents by Reference.
The
registrant is subject to the informational and reporting
requirements of Sections 13(a), 14, and 15(d) of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”),
and in accordance therewith files reports, proxy statements and
other information with the Securities and Exchange Commission, or
the SEC. The following documents, which are on file with the SEC,
are incorporated in this Registration Statement by
reference:
(a) The
registrant’s Annual Report on Form 10-K for the fiscal year
ended September 30, 2019, filed with the SEC on December 12,
2019;
(b) The
registrant’s Current Reports on Form 8-K filed on January 6,
2020 and January 9, 2020; and
(c) The
description of the registrant’s Common Shares contained in
the registrant’s Registration Statement on Form 8-A filed
with the SEC on November 3, 2015, including any amendment or report
filed for the purposes of updating such description.
In
addition, all documents filed by the registrant pursuant to
Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, after the
date hereof and prior to the filing of a post-effective amendment
which indicates that all securities offered herein have been sold
or which deregisters all securities then remaining unsold, shall be
deemed to be incorporated by reference herein and to be part hereof
from the date of filing such documents. Any statement contained
herein or in a document incorporated by reference or deemed to be
incorporated by reference herein shall be deemed to be modified or
superseded for purposes of this Registration Statement to the
extent that such statement is modified or superseded by any other
subsequently filed document which is incorporated or is deemed to
be incorporated by reference herein. Any such statement so modified
or superseded shall not be deemed, except as so modified or
superseded, to constitute a part of this Registration
Statement.
Item 4. Description of Securities.
Not
applicable.
Item 5. Interests of Named Experts and Counsel.
Not
applicable.
Item 6. Indemnification of Directors and Officers.
Subject
to the British Columbia Business
Corporations Act, or “the Act”, our directors, former
directors and alternate directors and their heirs and legal
personal representatives are indemnified against any judgment,
penalty or fine awarded or imposed in, or an amount paid in
settlement of, a stipulated legal or investigative proceeding, as
set forth in our Articles. In addition, our Articles provide that
we may, subject to any restrictions in the Act, indemnify any
person.
Under the Act, we may indemnify (a) a current or former
director or officer of the Company; (b) a current or former
director or officer of another corporation at a time when that
corporation is or was an affiliate of the Company; (c) a
current or former director or officer of another corporation who
holds or held such position at the request of the Company; or
(d) an individual who at the request of the Company, is or
was, or holds or held a position equivalent to that of, a director,
or officer of a partnership, trust, joint venture or other
unincorporated entity (collectively, an “Eligible
Party”). In certain circumstances an Eligible Party will
include the heirs and personal or other legal representatives of an
Eligible Party. We may indemnify an Eligible Party against any
Eligible Penalty (defined below) to which the Eligible Party is or
may be liable. After the final disposition of an Eligible
Proceeding (defined below), we may pay all Expenses (defined below)
actually and reasonably incurred by the Eligible Party in
connection with such Proceeding (defined below) and must pay all
such Expenses actually and reasonably incurred by the Eligible
Party in connection with such Proceeding if the Eligible Party has
not been reimbursed for those Expenses and is wholly successful on
the merits or otherwise in the outcome of the Proceeding. Among
other circumstances, we shall not indemnify or cover the Expenses
of an Eligible Party if the Eligible Party did not act honestly and
in good faith with a view to the best interests of the Company or
if the Eligible Party (other than in connection with a civil
Proceeding) did not have reasonable grounds for believing that the
Eligible Party’s conduct in respect of which the Proceeding
was brought was lawful. Further, we cannot indemnify or cover the
Expenses of an Eligible Party in respect of any Proceeding brought
by or on behalf of the Company against an Eligible Party. The
Supreme Court of British Columbia may, among other things, on the
applications of a corporation or an Eligible Party, order
indemnification by the Company of any liability or expense incurred
by an Eligible Party.
“Eligible Penalty” means a judgment, penalty or fine
awarded or imposed in, or an amount paid in settlement of, an
Eligible Proceeding.
“Eligible Proceeding” means any legal proceeding or
investigative action, whether current, threatened, pending or
completed (each, a “Proceeding”), in which an Eligible
Party, or any of the Eligible Party’s heirs and personal or
other legal representatives (i) is or may be joined as a
party, or (ii) is or may be liable for or in respect of a
judgment, penalty or fine in, or Expenses related to, such
Proceeding, in each case by reason of the Eligible Party’s
being or having been a director or officer of, or holding or having
held a position equivalent to that of a director or officer of, the
Company, one of its current or former subsidiaries or affiliates,
or another entity at the Company’s request.
“Expenses” includes costs, charges and expenses,
including legal and other fees, but does not include judgments,
penalties, fines or amounts paid in settlement of a
Proceeding.
We have also entered into separate indemnification agreements with
each of our directors and executive officers, which are intended to
indemnify our directors and executive officers to the fullest
extent permitted under the laws of the Province of British
Columbia, subject to certain exceptions. Our obligations under such
separate indemnification agreements are in addition to our
indemnification obligations under the Act and our charter
documents.
We
maintain a directors’ and officers’ liability insurance
policy, which insures directors and officers of the Company and its
subsidiaries for losses as a result of claims based upon the
directors’ and officers’ acts or omissions, including
liabilities arising under the Securities Act. The policy also
reimburses us for payments made pursuant to the indemnity
provisions under the Act and our charter documents.
Insofar as indemnification for liabilities arising under the
Securities Act may be permitted to directors, officers or persons
controlling the Registrant pursuant to the foregoing provisions,
the Registrant has been informed that in the opinion of the U.S.
Securities and Exchange Commission such indemnification is against
public policy as expressed in the Securities Act and is therefore
unenforceable.
Item 7. Exemption from Registration Claimed.
Not
applicable.
Item 8. Exhibits.
Exhibit
Number
|
|
Description
|
|
|
|
5.1
|
|
Opinion of
Fasken Martineau
Dumoulin LLP
|
|
|
|
|
|
Edesa Biotech, Inc.
2019 Equity Incentive Compensation Plan (incorporated by reference
to Exhibit 10.1 to the Company’s Current Report on Form 8-K
filed with the U.S. Securities and Exchange Commission on October
25, 2019)
|
|
|
|
23.1
|
|
Consent of
Independent Registered Public Accounting Firm
|
|
|
|
23.2
|
|
Consent of
Fasken Martineau
Dumoulin LLP (contained in the opinion filed as Exhibit
5.1 to this registration statement)
|
|
|
|
24.1
|
|
Power of Attorney
(included on signature page to this registration
statement)
|
Item 9. Undertakings.
(a)
The undersigned
registrant hereby undertakes:
(1)
To
file, during any period in which offers or sales are being made, a
post-effective amendment to this Registration
Statement:
(i)
To
include any prospectus required by Section 10(a)(3) of the
Securities Act;
(ii)
To
reflect in the prospectus any facts or events arising after the
effective date of the Registration Statement (or the most recent
post-effective amendment thereof) which, individually or in the
aggregate, represent a fundamental change in the information set
forth in the Registration Statement; and
(iii)
To
include any material information with respect to the plan of
distribution not previously disclosed in the Registration Statement
or any material change to such information in the Registration
Statement;
provided, however, that paragraphs
(a)(1)(i) and (a)(1)(ii) above do not apply if the information
required to be included in a post-effective amendment by those
paragraphs is contained in reports filed with or furnished to the
Commission by the registrant pursuant to Section 13 or Section
15(d) of the Exchange Act that are incorporated by reference in the
Registration Statement.
(2)
That,
for the purpose of determining any liability under the Securities
Act, each such post-effective amendment shall be deemed to be a new
registration statement relating to the securities offered therein,
and the offering of such securities at that time shall be deemed to
be the initial bona fide
offering thereof.
(3)
To
remove from registration by means of a post-effective amendment any
of the securities being registered which remain unsold at the
termination of the offering.
(b)
The undersigned
registrant hereby undertakes that, for purposes of determining any
liability under the Securities Act, each filing of the
registrant’s annual report pursuant to Section 13(a) or
Section 15(d) of the Exchange Act (and, where applicable, each
filing of an employee benefit plan’s annual report pursuant
to Section 15(d) of the Exchange Act) that is incorporated by
reference in the Registration Statement shall be deemed to be a new
registration statement relating to the securities offered therein,
and the offering of such securities at that time shall be deemed to
be the initial bona fide offering
thereof.
(c)
Insofar as
indemnification for liabilities arising under the Securities Act
may be permitted to directors, officers and controlling persons of
the Registrant pursuant to the foregoing provisions, or otherwise,
the Registrant has been advised that in the opinion of the SEC such
indemnification is against public policy as expressed in the
Securities Act and is, therefore, unenforceable. In the event that
a claim for indemnification against such liabilities (other than
the payment by the Registrant of expenses incurred or paid by a
director, officer or controlling person of the registrant in the
successful defense of any action, suit or proceeding) is asserted
by such director, officer or controlling person in connection with
the securities being registered, the registrant will, unless in the
opinion of its counsel the matter has been settled by controlling
precedent, submit to a court of appropriate jurisdiction the
question whether such indemnification by it is against public
policy as expressed in the Securities Act and will be governed by
the final adjudication of such issue.
SIGNATURES
Pursuant to the
requirements of the Securities Act of 1933, as amended, the
registrant certifies that it has reasonable grounds to believe that
it meets all of the requirements for filing on Form S-8 and has
duly caused this registration statement to be signed on its behalf
by the undersigned, thereunto duly authorized, in the City of Markham,
Province of Ontario, on January 28, 2020.
|
EDESA
BIOTECH, INC.
|
|
|
|
|
|
|
By:
|
/s/ Michael
Brooks
|
|
|
|
Michael
Brooks
|
|
|
|
President
|
|
KNOW ALL PERSONS BY THESE PRESENTS, that
each person whose signature appears below constitutes and appoints
Pardeep Nijhawan and Kathi Niffenegger as such person’s true
and lawful attorney-in-fact and agent, each with full power of
substitution and resubstitution, for such person in such
person’s name, place and stead, in any and all capacities, to
sign any and all amendments (including post-effective amendments)
to this Registration Statement, and to file the same, with all
exhibits thereto, and other documents in connection therewith, with
the Securities and Exchange Commission, granting unto said
attorneys-in-fact and agents, and each of them, full power and
authority to do and perform each and every act and thing requisite
and necessary to be done in connection therewith, as fully to all
intents and purposes as he or she might or could do in person,
hereby ratifying and confirming all that said attorneys-in-fact and
agents, or any of them, or his or her substitute or substitutes,
may lawfully do or cause to be done by virtue hereof.
Pursuant to the
requirements of the Securities Act of 1933, this Registration
Statement has been signed by the following persons in the
capacities and on the date indicated.
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
/s/
Pardeep Nijhawan
|
|
Director,
Chief Executive Officer and Corporate Secretary (Principal
Executive Officer)
|
|
January
28, 2020
|
Pardeep
Nijhawan
|
|
|
|
|
|
|
|
|
|
/s/
Kathi Niffenegger
|
|
Chief
Financial Officer (Principal Financial and Accounting
Officer)
|
|
January
28, 2020
|
Kathi
Niffenegger
|
|
|
|
|
|
|
|
|
|
/s/
Lorin Johnson
|
|
Director
|
|
January
28, 2020
|
Lorin
Johnson
|
|
|
|
|
|
|
|
|
|
/s/
Sean McDonald
|
|
Director
|
|
January
28, 2020
|
Sean
McDonald
|
|
|
|
|
|
|
|
|
|
/s/
Frank Oakes
|
|
Director
|
|
January
28, 2020
|
Frank
Oakes
|
|
|
|
|
|
|
|
|
|
/s/
Paul Pay
|
|
Director
|
|
January
28, 2020
|
Paul
Pay
|
|
|
|
|
|
|
|
|
|
/s/
Carlo Sistilli
|
|
Director
|
|
January
28, 2020
|
Carlo
Sistilli
|
|
|
|
|
|
|
|
|
|
/s/
Peter van der Velden
|
|
Director
|
|
January
28, 2020
|
Peter
van der Velden
|
|
|
|
|
Edesa Biotech (NASDAQ:EDSA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Edesa Biotech (NASDAQ:EDSA)
Historical Stock Chart
From Sep 2023 to Sep 2024